{"protocolSection":{"identificationModule":{"nctId":"NCT06474975","orgStudyIdInfo":{"id":"L2-092"},"organization":{"fullName":"European Institute of Oncology","class":"OTHER"},"briefTitle":"Intra-SURGerY High-resolution Specimen PET/CT Imager for Margin Assessment in Early-stage Breast Cancer","officialTitle":"SURGYPET: Intra-SURGerY High-resolution Specimen PET/CT Imager for Margin Assessment in Early-stage Breast Cancer as Compared to Gross Pathology: a Prospective Non-inferiority Analysis","acronym":"SURGYPET"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-20","studyFirstSubmitQcDate":"2024-06-20","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-20","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"European Institute of Oncology","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is a diagnostic open-label, prospective, single-arm non-inferiority clinical trial.\n\nThe primary endpoint is the accuracy to detect positive invasive margins in invasive ductal carcinoma (IDC) patients by high-resolution specimen Positron Emission Tomography/Computed Tomography (PET/CT) imaging.","detailedDescription":"The rationale of this study is to examine the non-inferiority of intraoperative high-resolution specimen PET/CT imaging in early-stage breast cancer for the identification of all positive margins of the invasive component during Breast Cancer Surgery (BCS) as compared to standard-of-care gross pathology evaluation.\n\nThe PET/CT specimen imager is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard."},"conditionsModule":{"conditions":["Breast Cancer","Breast-conserving Surgery"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Identification of positive margins with PET/CT specimen imager","type":"EXPERIMENTAL","description":"Identification of all positive margins of the invasive component during BCS using PET/CT specimen imager","interventionNames":["Device: AURA 10 PET/CT"]}],"interventions":[{"type":"DEVICE","name":"AURA 10 PET/CT","description":"The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard","armGroupLabels":["Identification of positive margins with PET/CT specimen imager"],"otherNames":["PET/CT specimen imager (AURA 10 PET/CT)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Evaluation of the accuracy to detect positive invasive margins in IDC patients","description":"Evaluation of intraoperative high-resolution specimen PET/CT imaging for the identification of all invasive positive margins during primary breast-conserving surgery (BCS) of invasive ductal carcinoma (IDC), as compared to perioperative gross pathology evaluation. Permanent pathology is used as the gold standard for margin assessment.","timeFrame":"1 month"}],"secondaryOutcomes":[{"measure":"Evaluation of diagnostic performance of PET/CT in the detection of positive margins respect to gross pathology","description":"determining the diagnostic performance of intraoperative high-resolution specimen PET/CT imaging and gross pathology to detect all positive margin;","timeFrame":"1 month"},{"measure":"Detection of malignant cells in resected lymph nodes and cavity shaves","description":"exploring the ability of intraoperative high-resolution specimen PET/CT imaging to detect the presence of malignant cells in resected lymph nodes and cavity shaves;","timeFrame":"1 month"},{"measure":"Definition of optimal SUVmax cut-off","description":"determining the optimal SUVmax cut-off in intraoperative high-resolution specimen PET/CT imaging for the correct detection of malignant vs. non-malignant tissues, using pathology results as standard-of-reference","timeFrame":"1 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* females with an age over 18 years;\n* confirmed breast cancer with indication to undergo BCS (stage I-II with tumor â‰¤2.5 in greatest dimension);\n* vacuum-assisted core breast biopsy is allowed for non-invasive tumors only;\n* able to understand treatment protocol and informed consent form;\n* estimated by the investigator to be compliant for study participation.\n\nExclusion Criteria:\n\n* general or local contra-indication for BCS;\n* previous breast surgery;\n* inflammatory breast cancer;\n* radiotherapy of the ipsilateral breast;\n* vacuum-assisted core breast biopsy for all patients with invasive tumors (vacuum-assisted core breast biopsy is allowed for patients with non-invasive tumors as long as the residual tumor size on mammogram is at least 1.0 cm);\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year;\n* active bacterial, viral or fungal infection.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Francesco Ceci, MD","role":"CONTACT","phone":"+390257489315","email":"francesco.ceci@ieo.it"},{"name":"Francesco Mattana","role":"CONTACT","phone":"+390257489315","email":"francesco.mattana@ieo.it"}],"overallOfficials":[{"name":"Francesco Ceci","affiliation":"European Institute of Oncology","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"European Institute of Oncology","city":"Milan","country":"Italy","contacts":[{"name":"Francesco Ceci","role":"CONTACT"}],"geoPoint":{"lat":45.46427,"lon":9.18951}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000001941","term":"Breast Diseases"},{"id":"D000012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Cancer","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}